ICUI

Based on ICU Medical, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does ICU Medical do?

ICU Medical develops and sells medical devices for infusion therapy and critical care. Its product range spans needlefree connectors, infusion pumps, closed system drug transfer devices, IV fluids, and medication management software — all aimed at improving safety and efficiency in hospital settings.

Does ICUI pay dividends?

ICU Medical does not currently pay a dividend. The company has historically directed capital toward product development and business integration rather than shareholder distributions. Investors seeking income should note this before adding ICUI to a dividend-focused portfolio.

When does ICUI report earnings?

ICU Medical follows a standard quarterly earnings cadence for US-listed companies. Specific upcoming report dates are not covered by our data source — check ICU Medical's investor relations page for the current schedule.

Is ICUI a good stock to buy?

UQS Score rates ICUI as Below Average, reflecting Weak readings across Quality, Moat, and Risk pillars. The Valuation pillar is Good, which may interest contrarian investors, but the broader pillar profile warrants careful review. See the full breakdown on UQS Pro.

Is ICUI overvalued?

The UQS Valuation pillar for ICUI is rated Good, suggesting the stock does not appear expensive relative to its fundamentals at current levels. However, valuation alone does not offset concerns in other areas — quality and risk factors remain important context.

How does ICUI compare to its competitors?

ICU Medical competes in the medical device and infusion therapy space alongside companies like Haemonetics and LeMaitre Vascular, each with distinct product focuses. ICUI's integrated portfolio of devices, fluids, and software is a differentiating factor, though its UQS profile currently trails stronger-rated peers in quality and moat.

What is ICUI's market cap bracket?

ICU Medical is classified as a mid-cap company. This places it in a tier where institutional coverage exists but the stock may see more volatility than large-cap medical device names during periods of market stress.

Who founded ICU Medical?

ICU Medical was founded in 1992. Detailed founding history, including founder names, is publicly available through the company's official corporate history and investor relations materials.

Is ICUI a long-term quality investment?

As a long-term quality indicator, ICUI's Below Average UQS Score — driven by Weak Quality, Moat, and Risk pillars — suggests the business has meaningful hurdles to clear before it would rank among higher-conviction long-term holdings. The Neutral Growth and Good Valuation pillars offer some balance, but durability of competitive position remains a concern.

What is the main competitive advantage of ICU Medical?

ICU Medical's broadest competitive asset is its integrated portfolio — combining physical devices, IV fluids, and software in a single vendor relationship for hospitals. However, the UQS Moat pillar rates this advantage as Weak, indicating that differentiation may not yet translate into durable pricing power or switching costs at scale.

What sector does ICUI belong to?

ICU Medical operates in the Healthcare sector, specifically within the medical devices and equipment segment. It serves acute care hospitals and healthcare systems globally, with products spanning infusion therapy, critical care monitoring, and IV fluid manufacturing.

Is ICUI a growth stock or value stock?

Based on its UQS profile, ICUI sits in an in-between position — the Growth pillar is Neutral, suggesting neither strong expansion nor contraction, while the Valuation pillar is Good. This combination may appeal to investors looking for a potentially undervalued turnaround rather than a pure growth or deep-value play.

ICU Medical, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

ICU Medical, Inc. shows steady but unspectacular growth, typical for mature companies.

ICU Medical, Inc. has some risk factors including moderate leverage or solvency concerns.

ICU Medical, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.

ICU Medical, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ICUI.

The UQS (Unified Quality Score) for ICU Medical, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses ICU Medical, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether ICU Medical, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.